Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment

Multikinase inhibitors (MKIs) have been the only first-line treatment for advanced hepatocellular carcinoma (HCC) for more than a decade, until the approval of immune checkpoint inhibitors (ICIs). Moreover, the combination regimen of atezolizumab (anti-programmed cell death protein ligand 1 antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ze-Long, Liu, Jing-Hua, Staiculescu, Daniel, Chen, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Immunotherapy in Hepatocellular Carcinoma: a New Kid on the Block
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150670/
https://www.ncbi.nlm.nih.gov/pubmed/34104226
http://dx.doi.org/10.1177/17588359211018026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150670/
https://www.ncbi.nlm.nih.gov/pubmed/34104226
http://dx.doi.org/10.1177/17588359211018026

Ejemplares similares